These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37966109)

  • 21. Early completion of phase I cancer clinical trials with Bayesian optimal interval design.
    Kojima M
    Stat Med; 2021 Jun; 40(14):3215-3226. PubMed ID: 33844323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
    Kojima M
    BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
    Silva RB; Yap C; Carvajal R; Lee SM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.
    Zhang H; Chiang AY; Wang J
    Stat Med; 2022 Nov; 41(27):5463-5483. PubMed ID: 35428037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
    Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
    Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
    Tighiouart M; Li Q; Piantadosi S; Rogatko A
    Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
    Tighiouart M; Liu Y; Rogatko A
    PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
    Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
    Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian optimal interval design with multiple toxicity constraints.
    Lin R
    Biometrics; 2018 Dec; 74(4):1320-1330. PubMed ID: 29870069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Escalation strategies for combination therapy Phase I trials.
    Sweeting MJ; Mander AP
    Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
    Diniz MA; Kim S; Tighiouart M
    J Probab Stat; 2018; 2018():. PubMed ID: 30906326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.